Clinical Trials
33 trialsNCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06119581 2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3 Recruiting
NCT05462717 2026-05-15
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Phase 1 Active not recruiting
NCT06606847 2026-05-15
LADOGA
AstraZeneca
Phase 2 Active not recruiting
NCT07185997 2026-05-11
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
ArriVent BioPharma, Inc.
Phase 3 Recruiting
NCT06128551 2026-04-23
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT03157128 2026-04-16
LIBRETTO-001
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT07279935 2026-03-19
REVIVE
AstraZeneca
Phase 4 Not yet recruiting
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT05941897 2026-03-05
LOTOS
AstraZeneca
Phase 2 Active not recruiting
NCT03899792 2026-01-06
LIBRETTO-121
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT05054725 2026-01-06
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
Phase 2 Completed
NCT06145750 2025-11-24
FIRSTLUNG
Delfi Diagnostics Inc.
Phase NA Completed
NCT07162883 2025-09-09
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT04774952 2025-04-15
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Completed
NCT04862780 2025-02-10
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated
NCT05241873 2025-02-10
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Blueprint Medicines Corporation
Phase 1 Terminated
NCT02826161 2023-11-15
CanStem43L
Sumitomo Pharma America, Inc.
Phase 3 Terminated
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT03989115 2023-06-26
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
Phase 1/2 Completed
NCT05153408 2023-06-18
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated
NCT03634982 2022-09-01
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Unknown
NCT02897778 2022-04-28
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
Syndax Pharmaceuticals
Phase 1 Completed
NCT02909452 2022-01-25
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Syndax Pharmaceuticals
Phase 1 Completed
NCT01594398 2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1 Completed
NCT01199068 2021-05-13
CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
Daiichi Sankyo
Phase 1 Completed
NCT01199055 2020-07-07
CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
Daiichi Sankyo
Phase 1 Completed
NCT03134872 2020-06-09
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT02941601 2019-09-27
A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 2 Withdrawn
NCT02602067 2018-09-18
Tenatumomab
sigma-tau i.f.r. S.p.A.
Phase 1 Terminated
NCT02134015 2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3 Terminated
NCT01039948 2015-04-08
A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
AVEO Pharmaceuticals, Inc.
Phase 1/2 Completed